Summary

Systemic Sclerosis Treatment: Global Industry Analysis 2018-2022 and Opportunity Assessment 2023-2033

A recent market study published by FMI on Systemic Sclerosis Treatment offers a global industry analysis for 2018-2022 and opportunity assessment for 2023-2033. The study offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical and current growth parameters, the growth prospects of the market are obtained with maximum precision.

Market Segmentation

By Therapeutics:

• Drug Therapy
• Hematopoietic Stem Cell Transplantation (HSCT)

By Indication:

• Limited Cutaneous Systemic Sclerosis Lamotrigine
• Diffuse Cutaneous Systemic Sclerosis

By Target Organ:

• Skin Fibrosis
• Musculoskeletal
• Digital Ulcers
• Pulmonary Arterial Hypertension
• Gastrointestinal
• Pulmonary Fibrosis
• Scleroderma Renal Crisis

By Route of Administration:

• Injectable
• Oral
• Topical

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Report Chapters

Executive Summary

The executive summary of the Systemic Sclerosis Treatment includes the global market outlook, demand side trends, supply side trends and also include FMI analysis and recommendations of Systemic Sclerosis Treatment.

Chapter 01 - Market Overview

Readers can find the detailed segmentation and definition of the Systemic Sclerosis Treatment in this chapter, which will help to understand basic information about Systemic Sclerosis Treatment. This section also highlights the market scope, taxonomy and limitations which help the reader understand the market coverage of Systemic Sclerosis Treatment report.

Chapter 02 - Market Background

This chapter includes detailed analysis of the By Therapeutics processing methods overview, consumer buying patterns & tendencies and policy developments and regulatory scenario. It also includes in depth analysis of macro-economic factors and covers topics like global GDP growth outlook, global industry value added, personal consumption, expenditures, modern trade penetration and consumer price indices. The chapter also covers forecast factors - relevance & impact, value chain analysis and market dynamics (drivers, restraints and opportunities) to better understand the market.

Chapter 03 - Global Systemic Sclerosis Treatment Demand Analysis 2018-2022 and Forecast, 2023-2033

The chapter include historical market value (USD 928.1 Million) analysis (2018-2022) and current and future market value (USD 2.2 Billion) and volume (7.9%) projections (2023-2033). The projections are based on the Y-O-Y growth trend analysis and absolute $ opportunity analysis country of operation.

Chapter 04 - Global Systemic Sclerosis Treatment - Pricing Analysis

Based on By Therapeutics, the pricing analysis chapter include Regional pricing analysis (USD/MT), global average pricing analysis benchmark, and key factors impacting the pricing.

Chapter 05 - Global Systemic Sclerosis Treatment Analysis 2018-2022 and Forecast 2023-2033, By Therapeutics

Based on By Therapeutics, Systemic Sclerosis Treatment is segmented into By Drug Therapy, Hematopoietic Stem Cell Transplantation (HSCT). Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Therapeutics.


Chapter 06 - Global Systemic Sclerosis Treatment Analysis 2018-2022 and Forecast 2023-2033, By Indication

Based on By Indication, Systemic Sclerosis Treatment is segmented into Limited Cutaneous Systemic Sclerosis Lamotrigine, Diffuse Cutaneous Systemic Sclerosis. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Indication.

Chapter 07 - Global Systemic Sclerosis Treatment Analysis 2018-2022 and Forecast 2023-2033, By Target Organ

Based on By Target Organ, Systemic Sclerosis Treatment is segmented into Skin Fibrosis, Musculoskeletal, Digital Ulcers, Pulmonary Arterial Hypertension, Gastrointestinal, Pulmonary Fibrosis, Scleroderma Renal Crisis. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Target Organ.

Chapter 08 - Global Systemic Sclerosis Treatment Analysis 2018-2022 and Forecast 2023-2033, By Route of Administration

Based on By Route of Administration, Systemic Sclerosis Treatment is segmented into Injectable, Oral, Topical. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Route of Administration.



Chapter 09 - Global Systemic Sclerosis Treatment Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel

Based on By Distribution Channel, Systemic Sclerosis Treatment is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics. This section also offers market attractiveness analysis based on By Distribution Channel. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Distribution Channel.

Chapter 10 - Systemic Sclerosis Treatment Analysis 2018-2022 and Forecast 2023-2033, By Region

Based on By Region, Systemic Sclerosis Treatment is segmented into North America, Latin America, Europe, East Asia, South Asia, Oceania and MEA. This section also offers market attractiveness analysis based on By Region. Readers can also find value forecast and Y-o-Y growth comparison for all above mentioned By Region.

Chapter 11 - North America Systemic Sclerosis Treatment Analysis 2018-2022 and Forecast 2023-2033

This chapter includes a detailed analysis of the growth of the Systemic Sclerosis Treatment in the North American region, along with a country-wise assessment that includes the US and Canada. Readers can also find regional trends, regulations, and market growth based on different segment and countries in the North America region.

Chapter 12 - Latin America Systemic Sclerosis Treatment Analysis 2018-2022 and Forecast 2023-2033

This chapter includes a detailed analysis of the growth of Systemic Sclerosis Treatment in the Latin America region, along with a country-wise assessment that includes the Brazil, Mexico, Chile, Argentina, Peru and Rest of Latin America. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Systemic Sclerosis Treatment in the Latin America region.

Chapter 13 - Europe Systemic Sclerosis Treatment Analysis 2018-2022 and Forecast 2023-2033

This chapter includes a detailed analysis of the growth of Systemic Sclerosis Treatment in the European region, along with a country-wise assessment that includes the Germany, Italy, France, U.K., Spain, Russia, Nordic, Benelux and Rest of Europe. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Systemic Sclerosis Treatment in the regional market.

Chapter 14 - East Asia Systemic Sclerosis Treatment Analysis 2018-2022 and Forecast 2023-2033

This chapter includes a detailed analysis of the growth of Systemic Sclerosis Treatment in the East Asia region, along with a country-wise assessment that includes the China, Japan, and South Korea. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Systemic Sclerosis Treatment in the regional market.

Chapter 15 - South Asia Systemic Sclerosis Treatment Analysis 2018-2022 and Forecast 2023-2033

This chapter includes a detailed analysis of the growth of Systemic Sclerosis Treatment in the South Asia region, along with a country-wise assessment that includes the India, Indonesia, Malaysia, Thailand, and Rest of South Asia. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Systemic Sclerosis Treatment in the regional market.

Chapter 16 - Middle East and Africa Systemic Sclerosis Treatment Analysis 2018-2022 and Forecast 2023-2033

This chapter includes a detailed analysis of the growth of Systemic Sclerosis Treatment in the MEA region, along with a country-wise assessment that includes the GCC Countries, South Africa, North Africa, Turkey and Rest of MEA. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Systemic Sclerosis Treatment in the regional market.

Chapter 17 - Key Countries Systemic Sclerosis Treatment Analysis 2018-2022 and Forecast 2023-2033

This chapter offers insights into how the Systemic Sclerosis Treatment is expected to grow in major countries globally.

Chapter 18 - Market Structure Analysis- Global Assessment

This chapter includes company dashboard, industry structure analysis by tier of companies, 2022E, company share analysis of top players, 2022E, and competition benchmarking- matrix.

Chapter 19 - Competition Deep Dive (Tentative List)

This chapter includes company overview, By Therapeutics portfolio of companies, profitability by market segments, sales footprint, SWOT analysis and strategy overview of the companies being studied in the report. Some of the market players featured in the report are Medtronic Plc; GlaxoSmithKline Plc; Lupin Ltd; Johnson & Johnson Services Inc.; Bayer Healthcare LLC; F. Hoffmann-La Roche Ltd; Amgen Inc; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Zydus Lifescience Ltd.; Organon LLC; Accord Healthcare Inc.; Pfizer, Inc.; Sanofi S.A.; Cipla Ltd.

Chapter 20 - Assumptions and Acronyms

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the Systemic Sclerosis Treatment report.

Chapter 21 - Research Methodology

This chapter helps readers understand the research methodology followed to obtain various conclusions, as well as important qualitative and quantitative information, on Systemic Sclerosis Treatment.

ページTOPに戻る

Table of Contents

1. Executive Summary
2. Market Overview
3. Key Market Trends
4. Value Added Insights
5. Market Background
6. Global Market Demand (in Value or Size in USD Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutics
7.1. By Drugs Therapy
7.1.1. Corticosteroids
7.1.2. Immunosuppressant
7.1.3. Nonsteroidal Anti-inflammatory Drugs
7.1.4. Blood Pressure Medication
7.1.5. Proton Pump Inhibitors
7.1.6. TNF Inhibitors
7.1.7. Light Therapy
7.1.8. Nitroglycerin Ointment
7.1.9. Others
7.2. Hematopoietic Stem Cell Transplantation (HSCT)
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
8.1. Limited Cutaneous Systemic Sclerosis
8.2. Diffuse Cutaneous Systemic Sclerosis
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Target Organ
9.1. Skin Fibrosis
9.2. Musculoskeletal
9.3. Digital Ulcers
9.4. Pulmonary Arterial Hypertension
9.5. Gastrointestinal
9.6. Pulmonary Fibrosis
9.7. Scleroderma Renal Crisis
10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
10.1. Injectable
10.2. Oral
10.3. Topical
11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
11.1. Hospital Pharmacies
11.2. Specialty Clinics
11.3. Retail Pharmacies
11.4. Online Pharmacies
12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
12.1. North America
12.2. Latin America
12.3. Europe
12.4. East Asia
12.5. South Asia
12.6. Oceania
12.7. Middle East and Africa (MEA)
13. North America Analysis 2018 to 2022 and Forecast 2023 to 2033
14. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
15. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033
16. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
17. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
18. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033
19. Middle East and Africa (MEA) Market Analysis 2018 to 2022 and Forecast 2023 to 2033
20. Market Structure Analysis
21. Competition Analysis
21.1. Pfizer Inc.
21.2. Sanofi S.A.
21.3. Cipla Ltd.
21.4. Accord Healthcare Inc.
21.5. Organon LLC
21.6. Zydus Lifescience Ltd.
21.7. Teva Pharmaceutical Industries Ltd.
21.8. Novartis AG
21.9. Boehringer Ingelheim Pharmaceuticals, Inc.
21.10. Amgen Inc.
21.11. F. Hoffmann-La Roche Ltd.
21.12. Bayer Healthcare LLC
21.13. Johnson & Johnson Services Inc.
21.14. Lupin Ltd.
21.15. GlaxoSmithKline Plc
21.16. Medtronic Plc
22. Assumptions and Acronyms Used
23. Research Methodology